OneVentures

October was huge for OneVentures and our portfolio! Here are some of the highlights 👇 🌟 Phocas Software was acquired by Accel-KKR, a huge milestone for Australian technology! ❤️ Daniel Timms, BiVACOR Founder & CTO, was awarded the 2025 ASMR Medal by the Australian Society for Medical Research. 🦸 Employment Hero announced they had surpassed $300M ARR. 🤖 Flippa.com launched Lauren AI, a platform that finds and connects buyers with off-market online businesses. 🏆 Ben Thompson, Employment Hero Founder & CEO, was named the Technology category winner at the EY Entrepreneur of the Year Australia Awards. 🙅♂️ 🪡 Vaxxas announced their partnership with ObvioHealth to run needle-free vaccination trials using its HD-MAP platform and ObvioGo virtual research technology. 💡Dr Michelle Deaker, Ben Thompson and Daniel Timms were recognised in The Australian’s Top 100 Innovators List. 🎤 Sarah Meibusch represented OneVentures at AusBiotech as a speaker, moderator, chair and panellist. 🔬 ImmVirX presented clinical data on its oncolytic RNA therapy, IVX037 at ESMO, highlighting its activity in microsatellite stable colorectal cancer and ovarian cancer. 🧑⚖️ Paul Kelly was a judge for SXSW Sydney’s Startup Pitch: Health, Biotech and Medtech. 👷 MyPass Global was shortlisted as a finalist in the Software category for the Mining Magazine Awards 2025. 🎓 Anne-Marie Birkill was awarded a Vice-Chancellor’s Alumni Excellence Award from The University of Queensland. 🧑⚖️ Shawn Li joined the judging panel for Startmate’s Melbourne Pitch Night. 🚀 Fleet Space Technologies was named Australian Financial Review's most innovative company 2025.

Exciting news from Flippa.com on the launch of LaurenAI, an AI powered deal sourcing engine transforming how online businesses are acquired. Flippa’s mission is to democratise M&A for the creator and digital economy, building the world's first AI-powered platform dedicated to serving the 99% of businesses traditional M&A ignores.  LaurenAI builds on this vision by using real time data and machine learning to connect buyers with high quality online businesses faster and with greater precision. Congratulations to Blake Hutchison, Mark Harbottle, Matt Mickiewicz and the entire Flippa team. We’re proud to support you through our Growth Equity portfolio! 👇 Link in our comments for more information. 

If there’s ever been a time to run your next trial in Australia, it’s now. Speed, quality, global acceptance – and yes, up to a 43.5 % R&D rebate. That was the takeaway from my fireside chat with Megan Hooton , President of IQVIA Biotech, at AusBioInvest 2025 on “Smarter Trials, Stronger Returns.” Globally, biotech market has been characterised as volatile the last couple of years but hopefully this year we are seeing some hope- 💸 Start-ups have raised just US $17 B YTD — only 8 % of total VC, the lowest in two decades. 📈 Yet the LifeSci Biotech Index has climbed ~75 % since April. 🌏 And China-based sponsors now run 30 % of all global trials and nearly 40 % of oncology — up from 5 % a decade ago. Capital is scarce, competition fierce. The winners are those executing with precision: adaptive designs, smarter site selection, data-driven recruitment. That’s where Australia shines — world-class investigators, globally accepted data, rapid start-up, and a cost profile that extends runway by months (and millions). As I said in closing: Smarter design, lean execution and discipline are what differentiate winners today. Thank you Kerri Lee Sinclair and the whole AusBiotech team for bringing Meg to Australia to share her encyclopaedia of knowledge! And yes… #ProjectBringMegHome is officially underway 🇦🇺☕️ #biotech #venturecapital #clinicaltrials #AusBioInvest #Australia #innovation Photo credit: thank you Lis Boyce from Piper Alderman

Australia has built a strong foundation in life sciences research and clinical development through universities, research institutes and biotech companies, but how do we fund the next stage of growth to support scale-up and commercialisation? Last week was a busy one for our Partner Sarah Meibusch, who represented OneVentures across AusBiotech 2025 as a speaker, moderator, chair and panellist. Thanks to Stockhead for capturing some of Sarah’s key takeaways on building the funding pathways and partnerships needed to take Australia’s biotech sector from research to global scale 👇 🟠 Australia needs stronger mid-stage funding to help companies move from research and proof-of-concept to clinical trials and commercialisation. 🟠 Building patient capital and deeper local syndicates is essential to reduce reliance on offshore funding and sustain later-stage growth. 🟠 Australia’s cost-effective, high-quality clinical trial ecosystem offers a major opportunity to attract international investors and strengthen global connections. “Life sciences and biotech is nation building. It drives not just global health impact but also advanced manufacturing and sovereign capability,” - Sarah Meibusch Link in our comments for the full article 👇

We’re delighted to celebrate our Co-Founder Anne-Marie Birkill, who has been awarded with a Vice-Chancellor’s Alumni Excellence Award from The University of Queensland 👏 This honour recognises Anne-Marie’s for her pioneering investments in science and technology, advancing innovation and championing women’s leadership in business. UQ has played an important role in shaping Australia’s innovators, and it’s wonderful to see Anne-Marie recognised by the university where her journey in business and innovation began. At OneVentures, she’s been instrumental in helping founders turn world-class research into commercial success and inspires our entire team. Congratulations, Anne-Marie! https://lnkd.in/dwBTC4c3 UQ Business School

Huge congratulations to Dr Daniel Timms, Founder & CTO of BiVACOR, who has been awarded the 2025 ASMR Medal by the Australian Society for Medical Research. The award recognises Daniel’s pioneering work developing the BiVACOR Total Artificial Heart, a magnetic, rotary device that completely replaces the natural heart’s function and has the potential to transform treatment for patients with end-stage heart failure. The ASMR Medal is one of Australia’s highest honours in medical research, recognising outstanding individuals whose work has advanced health and scientific innovation. Daniel joins an esteemed group of past recipients celebrated for their leadership and lasting impact. 📹👇 Daniel shares the story of BiVACOR, from early prototypes built with his dad in Brisbane to witnessing the first in-human implant. Read more about Daniel’s ASMR Medal recognition 👉 https://lnkd.in/g8nj2-B5

Eight years ago I met Myles Glashier, Philip Dodds and Paul Magee when they were bootstrapping Phocas Software. From that first meeting, it was clear they had a big global market opportunity and were looking for a partner to help them unlock the potential in the business. In 2018, OneVentures were the first institutional investors in Phocas through our Fund II and I joined the board to support Myles, Paul and the leadership team as they began to scale globally. Today, I am so proud to see Phocas reach a major milestone with its acquisition by Accel-KKR. It is a recognition of years of hard work and exceptional leadership. Working alongside Myles, Paul, Phil, Dave Boorman and more recently Chairman David Pullini has been one of the most rewarding experiences of my career. Under Myles’ leadership as CEO, Phocas has evolved into a global category leader while staying true to the culture and values that have defined the company from the beginning.   This success is a testament to the incredible people who have built Phocas into what it is today, serving 2,800 customers and 48,000 monthly users worldwide. I cannot wait to see what happens in this exciting new chapter with A-KKR. Full Australian Financial Review article here: https://lnkd.in/gASHvE3i

Incredible recognition for Ben Thompson, who has been named the Technology category winner at the EY Entrepreneur Of The Year Australia awards👏 This award celebrates the entrepreneurial vision and impact driving Employment Hero’s mission to make employment easier and more valuable for everyone. Ben is a standout founder-CEO whose hard work and leadership have turned a bold idea into one of the world’s leading HR tech platforms. We’re proud to have backed Employment Hero and now to be continuing that journey as a company in our Growth Equity Portfolio. We recognise the entire team for their commitment to empowering small and medium businesses around the world Very well deserved!  

Brilliant news for Phocas Software on their acquisition by Accel-KKR👏 Congratulations to Myles Glashier, Paul Magee, Dave Boorman, Philip Dodds and the entire Phocas team on this incredible milestone! From the beginning, Phocas impressed us with its strong foundation built on a loyal and growing customer base, an exceptional leadership team and a standout culture. Over the years, that foundation has evolved into a global success story. The team has taken a great idea and built a category leader in business intelligence, financial planning and data analytics. "Partnering with the exceptional team at Phocas has been a privilege. During our investment, we witnessed the company grow into one of Australia’s standout success stories, and we’re confident it will continue to thrive with A-KKR’s backing" - Dr Michelle Deaker, Founding & Managing Partner, OneVentures. We were proud to be Phocas’ first institutional investor in 2018, supporting the team as they scaled and expanded internationally. This milestone is a testament to their vision and a great example of what’s possible for Australian technology companies on the global stage. We look forward to seeing what comes next! Full The Australian Financial Review article 👉 https://lnkd.in/gc_U266h